49 Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-2,290
Closed -$213K 200
2024
Q2
$213K Sell
2,290
-245
-10% -$22K 0.04% 138
2024
Q1
$238K Sell
2,535
-228
-8% -$21.2K 0.05% 104
2023
Q4
$247K Buy
+2,763
New +$205K 0.06% 95

Other funds holding XBI

49 Wealth Management's XBI Position: Q3 2024 in Review

49 Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 2,290 shares — an estimated $213K sold.

49 Wealth Management first reported a position in XBI in Q4 2023 and held it in 3 quarters. The position peaked at $247K in Q4 2023. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

  • 49 Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
  • 49 Wealth Management sold 2,290 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $213K.
  • 49 Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 3 quarters.
  • 49 Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $247K in Q4 2023.
  • 769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on 49 Wealth Management's 13F filing for Q3 2024, filed 12 Nov 2024.